Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Caitlin E. Cox

April 02, 2022

News Conference News ACC 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Yael L. Maxwell

May 26, 2021

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content